Clinical Rheumatology

, Volume 29, Issue 7, pp 729–737 | Cite as

Renal disease in systemic sclerosis with normal serum creatinine

  • Reem H. A. MohamedEmail author
  • Hania S. Zayed
  • Amr Amin
Original Article


Prognosis of systemic sclerosis largely depends on involvement of internal organs. The aim was to evaluate renal impairment in patients with systemic sclerosis by measuring the Glomerular filteration rate (GFR) and then calculating the GFR using the Cockgroft and Gault formula and the Modification of Diet in Renal Disease Equation (MDRD) formula. Thirty one scleroderma patients were recruited from the Rheumatology and Rehabilitation Department, Cairo University Hospitals, mean age 43.25 ± 11.28 years, 31 healthy controls were included. Disease severity was done using Medsger score. GFR was measured using classical Gates method TC99mDTPA. The modified Cockcroft and Gault formula and equation 7 from the MDRD were used for calculation of GFR. All patients had within normal serum creatinine levels. A normal GFR (>89ml/min) was found in 45.1%. Gates method showed reduced GFR was reported in 54.9%. Stage II chronic kidney disease (60-89 ml/min) found 32.3%, and stage III (30-59 ml/min) in 22.6%. The formulae used showed reduction of GFR in 35.29% of those affected by the Cockcroft-Gault and in 41.17% of those affected using the MDRD. No correlation to patients’ age, disease duration, or severity. A positive correlation was also reported between the presence of renal involvement and pulmonary vascular involvement p = 0.04. Gates method showed reduction of the GFR in 54.9% of the systemic sclerosis patients. The formulae used were not as precise as the measured GFR in diagnosing all cases with subclinical renal involvement. Patients with systemic sclerosis should be screened for renal involvement irrespective of disease severity or duration.


Systemic sclerosis Glomerular filteration rate Cockcroft and Gault Modification of Diet in renal disease equation 



Our thanks to the Department of Nuclear Medicine, Faculty of <edicine, Cairo University Hospitals for providing all the facilities needed for this research.




  1. 1.
    Haustein UF (2002) Systemic sclerosis-scleroderma. Dermatol Online 8(1):3Google Scholar
  2. 2.
    Silman AJ (1997) Scleroderma—demographics and survival. J Rheumatol 24:58–61Google Scholar
  3. 3.
    Altman RD, Medsger TA Jr, Bloch DA, Beat AM (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413CrossRefPubMedGoogle Scholar
  4. 4.
    Silman AJ, Jannini S, Symmons D, Bacon P (1988) An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 27:286–290CrossRefPubMedGoogle Scholar
  5. 5.
    Olschewski H, Ghofrani HA, Walmrathh D (1999) Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160:600–607PubMedGoogle Scholar
  6. 6.
    Haustein UF, Albrecht M (1993) Zur Epidemiologie und Klinik der systemischen Sklerodermie. Z Hautkrankh (H + G) 10:651–658Google Scholar
  7. 7.
    Steen VD, Medsger TA Jr (1990) Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 16:1–10PubMedGoogle Scholar
  8. 8.
    Medsger TA, Masi AT (1971) The epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 74:714–721PubMedGoogle Scholar
  9. 9.
    Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 11:2437–2444CrossRefGoogle Scholar
  10. 10.
    Steen VD (1996) Scleroderma renal crisis. Rheum Dis Clin North Am 22:861–878CrossRefPubMedGoogle Scholar
  11. 11.
    Steen VD, Medsger TA, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP (1984) Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 76:779–786CrossRefPubMedGoogle Scholar
  12. 12.
    Guerini S, Cavazzana I, Venturelli C, Rozzi M, Turina S, Sottini L, Tardanico R, Franceschini F, Scolari F (2007) Renal involvement in systemic sclerosis. G Ital Nefrol 24(4):295–310PubMedGoogle Scholar
  13. 13.
    Denton CP (2008) Renal manifestations of systemic sclerosis—clinical features and outcome assessment. Rheumatology 47(Supplement 5):v54–v56CrossRefPubMedGoogle Scholar
  14. 14.
    Arnaud L, Huart A, Plaisier E et al (2007) ANCA-related crescentic glomerulonephritis in systemic sclerosis: revisiting the 'normotensive scleroderma renal crisis'. Clin Nephrol 68:165–170PubMedGoogle Scholar
  15. 15.
    Kamen DL, Wigley FM, Brown AN (2006) Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma: a different kind of renal crisis. J Rheumatol 33:1886–1888PubMedGoogle Scholar
  16. 16.
    Kingdon EJ, Knight CJ, Dustan K, Irwin AG, Thomas M, Powis SH, Burns A, Hilson AJW, Black CM (2003) Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology 42:26–33CrossRefPubMedGoogle Scholar
  17. 17.
    Steen VD, Syzd A, Johnson JP et al (2005) Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 32:649–655PubMedGoogle Scholar
  18. 18.
    Penn H; Denton C.P. Diagnosis, management and prevention of scleroderma renal disease (2008) Curr Opin Rheumatol 20(6): 692-696Google Scholar
  19. 19.
    Mitch WE, Walser M (1978) A proposed mechanism for reduced creatinine excretion in severe chronic renal failure. Nephron 21:248–254CrossRefPubMedGoogle Scholar
  20. 20.
    El Nahas AM, Coles GA (1986) Dietary treatment of chronic renal failure: ten unanswered questions. Lancet 1:597–600CrossRefPubMedGoogle Scholar
  21. 21.
    Wibell L, Bjorsell-Ostling E (1973) Endogenous creatinine clearance in apparently healthy individuals as determined by 24 h ambulatory urine collection. Ups J Med Sci 78:43–47PubMedGoogle Scholar
  22. 22.
    Coresh J, Auguste P (2008) Reliability of GFR formulas based on serum creatinine, with special reference to the MDRD Study equation. Scand J Clin Lab Invest Suppl 241:30–38CrossRefPubMedGoogle Scholar
  23. 23.
    Chantler C, Garnett ES, Parsons V, Veall N (1969) Glomerular filtration rate measurement in man by the single injection methods using [51Cr] EDTA. Clin Sci 37:169–180PubMedGoogle Scholar
  24. 24.
    Perrone RD, Steinman TI, Beck GJ et al (1990) Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 16:224–35PubMedGoogle Scholar
  25. 25.
    Gates GF (1982) Glomerular filtration rate:Estimation from fractional renal accumulation of Tc-99m DTPA (stannous). AJR 138:565–570PubMedGoogle Scholar
  26. 26.
    Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Arthritis Rheum 23: 581–590Google Scholar
  27. 27.
    Haycock GB, Schwartz GJ, Wisotsky DH (1978) Geometric method for measuring body surface area: a height–weight formula validated in infants, children, and adults. J Pediatr 93:62–66CrossRefPubMedGoogle Scholar
  28. 28.
    Yusuke Inoue, Manabu Minami, Kuni Ohtomo. Isotopic scanning for Renal Disease (2004) Kidney Trans 15: 3, 257-264.Google Scholar
  29. 29.
    Bartels H, Bohmer M, Heierli C (1972) Serum creatinine determination without protein precipitation. Clin Chim Acta 37:193–197CrossRefPubMedGoogle Scholar
  30. 30.
    O'Leary N, Pembroke A, Duggan PF (1992) A simplified procedure for eliminating the negative interference of bilirubin in the Jaffe reaction for creatinine. Clin Chem 38:1749–1751PubMedGoogle Scholar
  31. 31.
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMedGoogle Scholar
  32. 32.
    Gault MH, Longerich LL, Harnett JD, Wesolowski C (1992) Predicting glomerular function from adjusted serum creatinine. Nephron 62:249–256CrossRefPubMedGoogle Scholar
  33. 33.
    National Kidney Foundation Kidney Disease, Outcome Quality Initiative Advisory Board. Clinical Practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Kidney disease quality initiative: Staging system and action planes for chronic kidney disease. Am J of kidney disease, 2002; 39(2suppl2): SI-246Google Scholar
  34. 34.
    Steen V.D., Renal involvement in systemic sclerosis (1994) Clin Dermatol. Apr-Jun 12(2):253-258.Google Scholar
  35. 35.
    Gupta R., Bammigatti C., Dinda A.K., Marwaha V., Gupta S. Prevalence of renal involvement in Indian patients with systemic sclerosis (2007). Ind Journ Med Sci 61 (2); 91-96.Google Scholar
  36. 36.
    Desai A, Goldschmidt RA, Kim GC (1990) Sequential development of pulmonary renal syndrome associated with c-ANCA 3 years after development of anti-GBM glomerulonephritis. Neph Dial Tran 22(3):926–929CrossRefGoogle Scholar
  37. 37.
    Guiduicci S, Matucci Cerinic M (2009) Vasculogenesis and angiogenesis: vascular damage in systemic sclerosis. Rheumatismo 61(2):81–83Google Scholar
  38. 38.
    Solanilla A, Villeneuve J, Auguste P, Hugues M, Alioum A, Lepreux I et al (2009) the transport of high amounts of vascular endothelial growth factors by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 48(9):1036–1044CrossRefGoogle Scholar
  39. 39.
    Papaioannou AL, Zakynthinos E, Kostikas K, Kiropoulos T, Koutsokera A, Ziogas A et al (2009) Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm Med 9:9–18CrossRefGoogle Scholar
  40. 40.
    Fleming JN, Nash RA, Mahoney WM Jr, Schwartz SM (2009) Curr Rheumatol Rep 11(2):103–110CrossRefPubMedGoogle Scholar
  41. 41.
    Denton CP, Black CM, Abraham DJ (2006) Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2:134–144. doi: 10.1038/ncprheum0115 CrossRefPubMedGoogle Scholar
  42. 42.
    Vytautas Kuzminskis, Inga Skarupskienė, Inga Arūnė Bumblytė, Žydrūnė Kardauskaitė, Jurgita Uogintaitė. Comparison of methods for evaluating renal function (Data of Kaunas University of Medicine Hospital in 2006). Online article, published May 2007.Google Scholar
  43. 43.
    Perazella M.A., Reilly R.F. Chronic kidney disease: a new classification and staging system (2003) Hospital Physician; 18-22.
  44. 44.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41CrossRefPubMedGoogle Scholar
  45. 45.
    Morgan DB, Dillon S, Payne RB (1978) The assessment of glomerular function: creatinine clearance or plasma creatinine? Postgrad Med J 54:302–310CrossRefPubMedGoogle Scholar
  46. 46.
    Broekroelofs J, Stegeman CA, Navis GJ et al (2000) Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable? J Heart Lung Trans 19:256–262CrossRefGoogle Scholar
  47. 47.
    Verhave J. C., Balje-Volkers, C. P; Hillege, H. L., DE Zeeuw, D., DE Jong, P. E. The reliability of different formulae to predict creatinine clearance (2003) J Int Med 253(5); 563-573Google Scholar
  48. 48.
    Wielosz E, Dryglewska M, Majdan M (2009 Aug) Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis. Clin Rheumatol 28(8):881–882Google Scholar

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  • Reem H. A. Mohamed
    • 1
    Email author
  • Hania S. Zayed
    • 1
  • Amr Amin
    • 2
  1. 1.Department of Rheumatology and Rehabilitation, Faculty of medicineCairo UniversityCairoEgypt
  2. 2.Department of Nuclear Medicine, Faculty of MedicineCairo UniversityCairoEgypt

Personalised recommendations